New Monoclonal Antibody Shows Promise for Rare Liver Disease

A recent Phase 2 clinical trial demonstrates that nebokitug, a new monoclonal antibody, is safe and shows potential efficacy for treating Primary Sclerosing Cholangitis (PSC), a rare liver disease. Published in the American Journal of Gastroenterology, these findings offer hope for patients with currently limited treatment options.

• Nebokitug, a monoclonal antibody, targets Primary Sclerosing Cholangitis (PSC).
• The treatment was found safe and well-tolerated in Phase 2 trials.
• It showed potential efficacy in reducing liver inflammation and fibrosis.
• Research led by UC Davis Health was published in a reputable medical journal.
• PSC is a rare liver disease with no effective approved treatments currently.
• Paves the way for crucial Phase 3 trials and potential FDA approval.

Read the full story on Quick Digest.